Academic Journal
View in EDS

Naldemedine for the Prevention of Recurrent Acute Pancreatitis:A Randomised, Double-Blind, Placebo-Controlled Trial

Bibliographic Details
Title: Naldemedine for the Prevention of Recurrent Acute Pancreatitis:A Randomised, Double-Blind, Placebo-Controlled Trial
Authors: Cook, Mathias E., Knoph, Cecilie S., Davidsen, Line, Frøkjær, Jens B., Bruun, Niels H., Novovic, Srdan, Hadi, Amer, Jørgensen, Maiken Thyregod, Mortensen, Michael B., Schaffalitzky, Ove, Nielsen, Liv B.J., Berner-Hansen, Mark, Drewes, Asbjørn M., Olesen, Søren S.
Source: Cook, M E, Knoph, C S, Davidsen, L, Frøkjær, J B, Bruun, N H, Novovic, S, Hadi, A, Jørgensen, M T, Mortensen, M B, Schaffalitzky, O, Nielsen, L B J, Berner-Hansen, M, Drewes, A M & Olesen, S S 2026, 'Naldemedine for the Prevention of Recurrent Acute Pancreatitis : A Randomised, Double-Blind, Placebo-Controlled Trial', United European Gastroenterology Journal, vol. 14, no. 1, e70178. https://doi.org/10.1002/ueg2.70178
Publication Year: 2026
Collection: University of Southern Denmark: Research Output / Syddansk Universitet
Subject Terms: naldemedine, opioid receptors, PAMORA, RCT, recurrent acute pancreatitis
Description: Background and aims: No medications are currently approved for the prevention of recurrent acute pancreatitis. This trial evaluated whether naldemedine, a peripherally acting μ-opioid receptor antagonist, reduces the risk of acute pancreatitis in patients with recurrent acute pancreatitis. Methods: This was a multicentre, double-blinded, placebo-controlled randomised trial conducted at four Danish pancreatitis referral centres. Participants aged 18–75 years with recurrent acute pancreatitis, both with and without a diagnosis of chronic pancreatitis, were randomised to receive naldemedine 0.2 mg or a matching placebo daily for up to 12 months. The primary outcome was acute pancreatitis recurrence, defined by the revised Atlanta Criteria. Secondary outcomes included pain flares, gastrointestinal symptoms, and quality of life. At the end of follow-up, the participant's global impression of change, safety and tolerability outcomes, new-onset diabetes and pancreatic exocrine insufficiency were assessed. Results: 74 participants (mean age: 46 years; 41% female) were randomised to naldemedine (n = 36) or placebo (n = 38). During a median follow-up time of 365 days (IQR, 352–370), participants in the naldemedine group had a numerically lower risk of acute pancreatitis compared to placebo (HR 0.54; 95% CI, 0.29–1.01; p = 0.05). No differences were observed between the groups for secondary efficacy, safety, and tolerability outcomes. Participants treated with naldemedine for at least 1 year had a lower risk of acute pancreatitis (HR 0.49; 95% CI, 0.24–0.97; p = 0.04). Conclusions: Treatment with naldemedine was safe and well-tolerated and may reduce the risk of recurrent acute pancreatitis. A larger confirmatory trial is needed to verify these findings. Trial registration: ClinicalTrials.gov Identifier: PAMORA-RAP: NCT04966559.
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
ISSN: 2050-6406
2050-6414
Relation: info:eu-repo/semantics/altIdentifier/pmid/41553774; info:eu-repo/semantics/altIdentifier/pissn/2050-6406; info:eu-repo/semantics/altIdentifier/eissn/2050-6414
DOI: 10.1002/ueg2.70178
Availability: https://portal.findresearcher.sdu.dk/da/publications/1e791b65-8935-4e87-9208-b3c9e842cd16
https://doi.org/10.1002/ueg2.70178
https://findresearcher.sdu.dk/ws/files/303253592/UEG_Journal_-_2026_-_Cook_-_Naldemedine_for_the_Prevention_of_Recurrent_Acute_Pancreatitis_A_Randomised_Double_Blind_.pdf
Rights: info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.AFB51B90
Database: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://portal.findresearcher.sdu.dk/da/publications/1e791b65-8935-4e87-9208-b3c9e842cd16#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
  – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:edsbas&genre=article&issn=20506406&ISBN=&volume=&issue=&date=20260101&spage=&pages=&title=Cook, M E, Knoph, C S, Davidsen, L, Frøkjær, J B, Bruun, N H, Novovic, S, Hadi, A, Jørgensen, M T, Mortensen, M B, Schaffalitzky, O, Nielsen, L B J, Berner-Hansen, M, Drewes, A M & Olesen, S S 2026, 'Naldemedine for the Prevention of Recurrent Acute Pancreatitis : A Randomised, Double-Blind, Placebo-Controlled Trial', United European Gastroenterology Journal, vol. 14, no. 1, e70178. https://doi.org/10.1002/ueg2.70178&atitle=Naldemedine%20for%20the%20Prevention%20of%20Recurrent%20Acute%20Pancreatitis%3AA%20Randomised%2C%20Double-Blind%2C%20Placebo-Controlled%20Trial&aulast=Cook%2C%20Mathias%20E.&id=DOI:10.1002/ueg2.70178
    Name: Full Text Finder (for New FTF UI) (ns324271)
    Category: fullText
    Text: Full Text Finder
    MouseOverText: Full Text Finder
Header DbId: edsbas
DbLabel: BASE
An: edsbas.AFB51B90
RelevancyScore: 1025
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1024.80883789063
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Naldemedine for the Prevention of Recurrent Acute Pancreatitis:A Randomised, Double-Blind, Placebo-Controlled Trial
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Cook%2C+Mathias+E%2E%22">Cook, Mathias E.</searchLink><br /><searchLink fieldCode="AR" term="%22Knoph%2C+Cecilie+S%2E%22">Knoph, Cecilie S.</searchLink><br /><searchLink fieldCode="AR" term="%22Davidsen%2C+Line%22">Davidsen, Line</searchLink><br /><searchLink fieldCode="AR" term="%22Frøkjær%2C+Jens+B%2E%22">Frøkjær, Jens B.</searchLink><br /><searchLink fieldCode="AR" term="%22Bruun%2C+Niels+H%2E%22">Bruun, Niels H.</searchLink><br /><searchLink fieldCode="AR" term="%22Novovic%2C+Srdan%22">Novovic, Srdan</searchLink><br /><searchLink fieldCode="AR" term="%22Hadi%2C+Amer%22">Hadi, Amer</searchLink><br /><searchLink fieldCode="AR" term="%22Jørgensen%2C+Maiken+Thyregod%22">Jørgensen, Maiken Thyregod</searchLink><br /><searchLink fieldCode="AR" term="%22Mortensen%2C+Michael+B%2E%22">Mortensen, Michael B.</searchLink><br /><searchLink fieldCode="AR" term="%22Schaffalitzky%2C+Ove%22">Schaffalitzky, Ove</searchLink><br /><searchLink fieldCode="AR" term="%22Nielsen%2C+Liv+B%2EJ%2E%22">Nielsen, Liv B.J.</searchLink><br /><searchLink fieldCode="AR" term="%22Berner-Hansen%2C+Mark%22">Berner-Hansen, Mark</searchLink><br /><searchLink fieldCode="AR" term="%22Drewes%2C+Asbjørn+M%2E%22">Drewes, Asbjørn M.</searchLink><br /><searchLink fieldCode="AR" term="%22Olesen%2C+Søren+S%2E%22">Olesen, Søren S.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Cook, M E, Knoph, C S, Davidsen, L, Frøkjær, J B, Bruun, N H, Novovic, S, Hadi, A, Jørgensen, M T, Mortensen, M B, Schaffalitzky, O, Nielsen, L B J, Berner-Hansen, M, Drewes, A M & Olesen, S S 2026, 'Naldemedine for the Prevention of Recurrent Acute Pancreatitis : A Randomised, Double-Blind, Placebo-Controlled Trial', United European Gastroenterology Journal, vol. 14, no. 1, e70178. https://doi.org/10.1002/ueg2.70178
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2026
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: University of Southern Denmark: Research Output / Syddansk Universitet
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22naldemedine%22">naldemedine</searchLink><br /><searchLink fieldCode="DE" term="%22opioid+receptors%22">opioid receptors</searchLink><br /><searchLink fieldCode="DE" term="%22PAMORA%22">PAMORA</searchLink><br /><searchLink fieldCode="DE" term="%22RCT%22">RCT</searchLink><br /><searchLink fieldCode="DE" term="%22recurrent+acute+pancreatitis%22">recurrent acute pancreatitis</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Background and aims: No medications are currently approved for the prevention of recurrent acute pancreatitis. This trial evaluated whether naldemedine, a peripherally acting μ-opioid receptor antagonist, reduces the risk of acute pancreatitis in patients with recurrent acute pancreatitis. Methods: This was a multicentre, double-blinded, placebo-controlled randomised trial conducted at four Danish pancreatitis referral centres. Participants aged 18–75 years with recurrent acute pancreatitis, both with and without a diagnosis of chronic pancreatitis, were randomised to receive naldemedine 0.2 mg or a matching placebo daily for up to 12 months. The primary outcome was acute pancreatitis recurrence, defined by the revised Atlanta Criteria. Secondary outcomes included pain flares, gastrointestinal symptoms, and quality of life. At the end of follow-up, the participant's global impression of change, safety and tolerability outcomes, new-onset diabetes and pancreatic exocrine insufficiency were assessed. Results: 74 participants (mean age: 46 years; 41% female) were randomised to naldemedine (n = 36) or placebo (n = 38). During a median follow-up time of 365 days (IQR, 352–370), participants in the naldemedine group had a numerically lower risk of acute pancreatitis compared to placebo (HR 0.54; 95% CI, 0.29–1.01; p = 0.05). No differences were observed between the groups for secondary efficacy, safety, and tolerability outcomes. Participants treated with naldemedine for at least 1 year had a lower risk of acute pancreatitis (HR 0.49; 95% CI, 0.24–0.97; p = 0.04). Conclusions: Treatment with naldemedine was safe and well-tolerated and may reduce the risk of recurrent acute pancreatitis. A larger confirmatory trial is needed to verify these findings. Trial registration: ClinicalTrials.gov Identifier: PAMORA-RAP: NCT04966559.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: application/pdf
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2050-6406<br />2050-6414
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: info:eu-repo/semantics/altIdentifier/pmid/41553774; info:eu-repo/semantics/altIdentifier/pissn/2050-6406; info:eu-repo/semantics/altIdentifier/eissn/2050-6414
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1002/ueg2.70178
– Name: URL
  Label: Availability
  Group: URL
  Data: https://portal.findresearcher.sdu.dk/da/publications/1e791b65-8935-4e87-9208-b3c9e842cd16<br />https://doi.org/10.1002/ueg2.70178<br />https://findresearcher.sdu.dk/ws/files/303253592/UEG_Journal_-_2026_-_Cook_-_Naldemedine_for_the_Prevention_of_Recurrent_Acute_Pancreatitis_A_Randomised_Double_Blind_.pdf
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by-nc-nd/4.0/
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.AFB51B90
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.AFB51B90
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/ueg2.70178
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: naldemedine
        Type: general
      – SubjectFull: opioid receptors
        Type: general
      – SubjectFull: PAMORA
        Type: general
      – SubjectFull: RCT
        Type: general
      – SubjectFull: recurrent acute pancreatitis
        Type: general
    Titles:
      – TitleFull: Naldemedine for the Prevention of Recurrent Acute Pancreatitis:A Randomised, Double-Blind, Placebo-Controlled Trial
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cook, Mathias E.
      – PersonEntity:
          Name:
            NameFull: Knoph, Cecilie S.
      – PersonEntity:
          Name:
            NameFull: Davidsen, Line
      – PersonEntity:
          Name:
            NameFull: Frøkjær, Jens B.
      – PersonEntity:
          Name:
            NameFull: Bruun, Niels H.
      – PersonEntity:
          Name:
            NameFull: Novovic, Srdan
      – PersonEntity:
          Name:
            NameFull: Hadi, Amer
      – PersonEntity:
          Name:
            NameFull: Jørgensen, Maiken Thyregod
      – PersonEntity:
          Name:
            NameFull: Mortensen, Michael B.
      – PersonEntity:
          Name:
            NameFull: Schaffalitzky, Ove
      – PersonEntity:
          Name:
            NameFull: Nielsen, Liv B.J.
      – PersonEntity:
          Name:
            NameFull: Berner-Hansen, Mark
      – PersonEntity:
          Name:
            NameFull: Drewes, Asbjørn M.
      – PersonEntity:
          Name:
            NameFull: Olesen, Søren S.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 20506406
            – Type: issn-print
              Value: 20506414
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
          Titles:
            – TitleFull: Cook, M E, Knoph, C S, Davidsen, L, Frøkjær, J B, Bruun, N H, Novovic, S, Hadi, A, Jørgensen, M T, Mortensen, M B, Schaffalitzky, O, Nielsen, L B J, Berner-Hansen, M, Drewes, A M & Olesen, S S 2026, 'Naldemedine for the Prevention of Recurrent Acute Pancreatitis : A Randomised, Double-Blind, Placebo-Controlled Trial', United European Gastroenterology Journal, vol. 14, no. 1, e70178. https://doi.org/10.1002/ueg2.70178
              Type: main
ResultId 1